Table 3. ACT HIV trial assessment schedule.

	DAYS                         MONTHS
	SCREENING	0	3	7	W eekly until discharge	30	60	M onthly to anti-TB drug end	12	18	24
ALL PARTICIPANTS
Eligibility assessment	(X)
Participant information sheet and consent	X
Randomisation		X
Clinical assessment	(X)	X	X	X	X	X	X	X	X	X	X
Disability assessment						X	X	X	X	X	X
Chest X-ray	(X)						X		X
Lumbar puncture (with paired plasma glucose) CSF Cryptococcal Ag test	(X) (X)					X	X
HIV test	(X)
EDTA blood for genetic tests Full blood count CD4 count HIV viral load Storage for later DNA extraction	(X) (X)	X X X		(X)			X
Sodium Urea/Creatinine ALT/ bilirubin Hepatitis C antibodies Hepatitis B surface antigen Fasting blood sugar/ HbA1c C-peptide/Lipids Strongyloides serology Serum Storage	(X) (X) (X)	X X X X X X		(X)	(X) (X) (X)		X	(X) (X)
Stool for Ova, cysts and parasites (Strongyloides) microscopy		X					X
SUBSET OF PARTICIPANTS RECRUITED TO IMAGING STUDY (HTD Vietnam only)
Brain MRI		X					X		X
SUBSET OF PARTICIPANTS RECRUITED TO HYPONATRAEMIA/ICP ANCILLARY STUDY (HTD Vietnam only)
24-hour fluid balance	(X)	X	X	X	X
Plasma sodium Plasma osmolality		X	X	X	X
Urinary sodium Urinary osmolality		X	X	X	X
Plasma cortisol		X
Ultra-sound assessment of intravascular volume		X	X	X	X
Ultra-sound measurement of optic nerve sheath diameter		X	X	X	X
SUBSET OF PARTICIPANTS RECRUITED TO ADRENAL SUPPRESSION ANCILLARY STUDY (HTD Vietnam only)
Synacthen test					X (day 21)		X